Neuromodulation for Craniofacial Pain and Headaches
Abstract
:1. Introduction
2. Literature Review
2.1. Occipital Nerves
2.1.1. Occipital Neuralgia
2.1.2. SUNCT/SUNHA
2.1.3. Hemicrania Continua
2.1.4. Trigeminal Neuralgia
2.1.5. Cluster Headache
2.1.6. Migraine
2.1.7. Complicated Migraine, Occipital Neuralgia, Combined
2.1.8. Primary Headache, Combined
2.1.9. Craniofacial Pain
2.2. Trigeminal Ganglion
2.2.1. Trigeminal Neuropathy
2.2.2. Trigeminal Neuralgia
2.3. Supraorbital/Supratrochlear Nerve
2.3.1. Postherpetic Neuralgia
2.3.2. Cluster Headache
2.3.3. Migraine
2.3.4. Hemiplegic Migraine
2.3.5. Supraorbital Neuralgia, Traumatic
2.4. Vagus Nerve
2.4.1. Non-Specific or Combination Primary Headache
2.4.2. SUNA
2.4.3. Hemicrania Continua
2.4.4. Cluster Headache
2.4.5. Migraine
2.5. Cervical Spinal Cord
2.5.1. Migraine
2.5.2. Cluster Headache
2.5.3. Post-Traumatic Headache
2.5.4. Postherpetic Neuralgia
2.6. Infraorbital Nerve
Cluster Headache
2.7. Great Auricular Nerve
2.7.1. Migraine
2.7.2. Post-Traumatic Headache
2.8. Auriculotemporal Nerve
2.8.1. Migraine
2.8.2. Chronic Headache
2.9. Sphenopalatine Ganglion
2.9.1. Migraine
2.9.2. Cluster Headache
2.9.3. Facial Pain
3. Complications
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Rizzoli, P.; Mullally, W.J. Headache. Am. J. Med. 2018, 131, 17–24. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, F. Headache disorders: Differentiating and managing the common subtypes. Br. J. Pain 2012, 6, 124–132. [Google Scholar] [CrossRef] [PubMed]
- Zakrzewska, J.M. Differential diagnosis of facial pain and guidelines for management. Br. J. Anaesth. 2013, 111, 95–104. [Google Scholar] [CrossRef] [PubMed]
- Lambru, G.; Elias, L.A.; Yakkaphan, P.; Renton, T. Migraine presenting as isolated facial pain: A prospective clinical analysis of 58 cases. Cephalalgia 2020, 40, 1250–1254. [Google Scholar] [CrossRef] [PubMed]
- Van Buyten, J.P. Trigeminal Ganglion Stimulation. Prog. Neurol. Surg. 2015, 29, 76–82. [Google Scholar] [CrossRef] [PubMed]
- Kustermans, L.; Van Buyten, J.P.; Smet, I.; Coucke, W.; Politis, C. Stimulation of the Gasserian ganglion in the treatment of refractory trigeminal neuropathy. J. Craniomaxillofac. Surg. 2017, 45, 39–46. [Google Scholar] [CrossRef]
- Elkholy, M.A.E.; Abd-Elsayed, A.; Raslan, A.M. Supraorbital Nerve Stimulation for Facial Pain. Curr. Pain Headache Rep. 2023, 27, 157–163. [Google Scholar] [CrossRef]
- Garcia, K.; Wray, J.K.; Kumar, S. Spinal Cord Stimulation. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK553154/ (accessed on 7 November 2023).
- Melzack, R.; Wall, P.D. Pain mechanisms: A new theory: A gate control system modulates sensory input from the skin before it evokes pain perception and response. Science 1965, 150, 971–979. [Google Scholar] [CrossRef]
- Sdrulla, A.D.; Guan, Y.; Raja, S.N. Spinal Cord Stimulation: Clinical Efficacy and Potential Mechanisms. Pain Pract. 2018, 18, 1048–1067. [Google Scholar] [CrossRef]
- Hassanzadeh, R.; Jones, J.C.; Ross, E.L. Neuromodulation for intractable headaches. Curr. Pain Headache Rep. 2014, 18, 392. [Google Scholar] [CrossRef]
- Kemp, W.J., 3rd; Tubbs, R.S.; Cohen-Gadol, A.A. The innervation of the scalp: A comprehensive review including anatomy, pathology, and neurosurgical correlates. Surg. Neurol. Int. 2011, 2, 178. [Google Scholar] [CrossRef] [PubMed]
- Weiner, R.L.; Reed, K.L. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999, 2, 217–221. [Google Scholar] [CrossRef] [PubMed]
- Moman, R.N.; Olatoye, O.O.; Pingree, M.J. Temporary, Percutaneous Peripheral Nerve Stimulation for Refractory Occipital Neuralgia. Pain Med. 2022, 23, 415–420. [Google Scholar] [CrossRef] [PubMed]
- Salmasi, V.; Olatoye, O.O.; Terkawi, A.S.; Hah, J.M.; Ottestad, E.; Pingree, M. Peripheral Nerve Stimulation for Occipital Neuralgia. Pain Med. 2020, 21 (Suppl. S1), S13–S17. [Google Scholar] [CrossRef] [PubMed]
- Oh, M.Y.; Ortega, J.; Bellotte, J.B.; Whiting, D.M.; Aló, K. Peripheral nerve stimulation for the treatment of occipital neuralgia and transformed migraine using a c1-2-3 subcutaneous paddle style electrode: A technical report. Neuromodulation 2004, 7, 103–112. [Google Scholar] [CrossRef]
- Kapural, L.; Mekhail, N.; Hayek, S.M.; Stanton-Hicks, M.; Malak, O. Occipital nerve electrical stimulation via the midline approach and subcutaneous surgical leads for treatment of severe occipital neuralgia: A pilot study. Anesth. Analg. 2005, 101, 171–174, table of contents. [Google Scholar] [CrossRef]
- Slavin, K.V.; Nersesyan, H.; Wess, C. Peripheral neurostimulation for treatment of intractable occipital neuralgia. Neurosurgery 2006, 58, 112–119. [Google Scholar] [CrossRef]
- Raoul, S.; Nguyen, J.M.; Kuhn, E.; de Chauvigny, E.; Lejczak, S.; Nguyen, J.P.; Nizard, J. Efficacy of Occipital Nerve Stimulation to Treat Refractory Occipital Headaches: A Single-Institution Study of 60 Patients. Neuromodulation 2020, 23, 789–795. [Google Scholar] [CrossRef]
- Miller, S.; Watkins, L.; Matharu, M. Long-term follow up of intractable chronic short lasting unilateral neuralgiform headache disorders treated with occipital nerve stimulation. Cephalalgia 2018, 38, 933–942. [Google Scholar] [CrossRef]
- Pascual, J. Treatment of hemicrania continua by occipital nerve stimulation with a bion device. Curr. Pain Headache Rep. 2009, 13, 3–4. [Google Scholar] [CrossRef]
- Balossier, A.; Donnet, A.; Régis, J.; Leplus, A.; Lantéri-Minet, M.; Fontaine, D. Occipital Nerve Stimulation for Recurrent Trigeminal Neuralgia Without Occipital Pain. Neuromodulation 2022, 7, 1795–1801. [Google Scholar] [CrossRef] [PubMed]
- Mueller, O.M.; Gaul, C.; Katsarava, Z.; Diener, H.C.; Sure, U.; Gasser, T. Occipital nerve stimulation for the treatment of chronic cluster headache—Lessons learned from 18 months experience. Cent. Eur. Neurosurg. 2011, 72, 84–89. [Google Scholar] [CrossRef] [PubMed]
- Magis, D.; Allena, M.; Bolla, M.; De Pasqua, V.; Remacle, J.M.; Schoenen, J. Occipital nerve stimulation for drug-resistant chronic cluster headache: A prospective pilot study. Lancet Neurol. 2007, 6, 314–321. [Google Scholar] [CrossRef] [PubMed]
- Magis, D.; Gerardy, P.-Y.; Remacle, J.-M.; Schoenen, J. Sustained Effectiveness of Occipital Nerve Stimulation in Drug-Resistant Chronic Cluster Headache. Headache J. Head Face Pain 2011, 51, 1191–1201. [Google Scholar] [CrossRef] [PubMed]
- Leone, M.; Proietti Cecchini, A.; Messina, G.; Franzini, A. Long-term occipital nerve stimulation for drug-resistant chronic cluster headache. Cephalalgia 2017, 37, 756–763. [Google Scholar] [CrossRef] [PubMed]
- Burns, B.; Watkins, L.; Goadsby, P.J. Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients. Neurology 2009, 72, 341–345. [Google Scholar] [CrossRef]
- Burns, B.; Watkins, L.; Goadsby, P.J. Treatment of medically intractable cluster headache by occipital nerve stimulation: Long-term follow-up of eight patients. Lancet 2007, 369, 1099–1106. [Google Scholar] [CrossRef]
- Fontaine, D.; Christophe Sol, J.; Raoul, S.; Fabre, N.; Geraud, G.; Magne, C.; Sakarovitch, C.; Lanteri-Minet, M. Treatment of refractory chronic cluster headache by chronic occipital nerve stimulation. Cephalalgia 2011, 31, 1101–1105. [Google Scholar] [CrossRef]
- Garcia-Ortega, R.; Edwards, T.; Moir, L.; Aziz, T.Z.; Green, A.L.; FitzGerald, J.J. Burst Occipital Nerve Stimulation for Chronic Migraine and Chronic Cluster Headache. Neuromodulation 2019, 22, 638–644. [Google Scholar] [CrossRef]
- Miller, S.; Watkins, L.; Matharu, M. Treatment of intractable chronic cluster headache by occipital nerve stimulation: A cohort of 51 patients. Eur. J. Neurol. 2017, 24, 381–390. [Google Scholar] [CrossRef]
- Fontaine, D.; Blond, S.; Lucas, C.; Regis, J.; Donnet, A.; Derrey, S.; Guegan-Massardier, E.; Jarraya, B.; Dang-Vu, B.; Bourdain, F.; et al. Occipital nerve stimulation improves the quality of life in medically-intractable chronic cluster headache: Results of an observational prospective study. Cephalalgia 2017, 37, 1173–1179. [Google Scholar] [CrossRef] [PubMed]
- Wilbrink, L.A.; de Coo, I.F.; Doesborg, P.G.G.; Mulleners, W.M.; Teernstra, O.P.M.; Bartels, E.C.; Burger, K.; Wille, F.; van Dongen, R.T.M.; Kurt, E.; et al. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): A randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurol. 2021, 20, 515–525. [Google Scholar] [CrossRef] [PubMed]
- Popeney, C.A.; Aló, K.M. Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 2003, 43, 369–375. [Google Scholar] [CrossRef] [PubMed]
- Rodrigo, D.; Acin, P.; Bermejo, P. Occipital Nerve Stimulation for Refractory Chronic Migraine: Results of a Long-Term Prospective Study. Pain Physician 2017, 20, E151–E159. [Google Scholar] [CrossRef] [PubMed]
- Ashkan, K.; Sokratous, G.; Göbel, H.; Mehta, V.; Gendolla, A.; Dowson, A.; Wodehouse, T.; Heinze, A.; Gaul, C. Peripheral nerve stimulation registry for intractable migraine headache (RELIEF): A real-life perspective on the utility of occipital nerve stimulation for chronic migraine. Acta Neurochir. 2020, 162, 3201–3211. [Google Scholar] [CrossRef] [PubMed]
- Schwedt, T.J.; Dodick, D.W.; Hentz, J.; Trentman, T.L.; Zimmerman, R.S. Occipital nerve stimulation for chronic headache--long-term safety and efficacy. Cephalalgia 2007, 27, 153–157. [Google Scholar] [CrossRef]
- Matharu, M.S.; Bartsch, T.; Ward, N.; Frackowiak, R.S.; Weiner, R.; Goadsby, P.J. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain 2004, 127 Pt 1, 220–230. [Google Scholar] [CrossRef]
- Serra, G.; Marchioretto, F. Occipital nerve stimulation for chronic migraine: A randomized trial. Pain Physician 2012, 15, 245–253. [Google Scholar] [CrossRef]
- Silberstein, S.D.; Dodick, D.W.; Saper, J.; Huh, B.; Slavin, K.V.; Sharan, A.; Reed, K.; Narouze, S.; Mogilner, A.; Goldstein, J.; et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012, 32, 1165–1179. [Google Scholar] [CrossRef]
- Saper, J.R.; Dodick, D.W.; Silberstein, S.D.; McCarville, S.; Sun, M.; Goadsby, P.J.; ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011, 31, 271–285. [Google Scholar] [CrossRef]
- Slotty, P.J.; Bara, G.; Kowatz, L.; Gendolla, A.; Wille, C.; Schu, S.; Vesper, J. Occipital nerve stimulation for chronic migraine: A randomized trial on subthreshold stimulation. Cephalalgia 2015, 35, 73–78. [Google Scholar] [CrossRef] [PubMed]
- Mekhail, N.A.; Estemalik, E.; Azer, G.; Davis, K.; Tepper, S.J. Safety and Efficacy of Occipital Nerves Stimulation for the Treatment of Chronic Migraines: Randomized, Double-blind, Controlled Single-center Experience. Pain Pract. 2017, 17, 669–677. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Dong, Z.; Wang, R.; Ao, R.; Han, X.; Tang, W.; Yu, S. Migraine Prevention Using Different Frequencies of Transcutaneous Occipital Nerve Stimulation: A Randomized Controlled Trial. J. Pain 2017, 18, 1006–1015. [Google Scholar] [CrossRef] [PubMed]
- Deshpande, K.K.; Wininger, K.L. Feasibility of combined epicranial temporal and occipital neurostimulation: Treatment of a challenging case of headache. Pain Physician 2011, 14, 37–44. [Google Scholar] [PubMed]
- Trentman, T.L.; Rosenfeld, D.M.; Vargas, B.B.; Schwedt, T.J.; Zimmerman, R.S.; Dodick, D.W. Greater occipital nerve stimulation via the Bion microstimulator: Implantation technique and stimulation parameters Clinical trial: NCT00205894. Pain Physician 2009, 12, 621–628. [Google Scholar] [CrossRef]
- Slavin, K.V.; Colpan, M.E.; Munawar, N.; Wess, C.; Nersesyan, H. Trigeminal and occipital peripheral nerve stimulation for craniofacial pain: A single-institution experience and review of the literature. Neurosurg. Focus 2006, 21, E5. [Google Scholar] [CrossRef]
- Chung, M.; Huh, R. Neuromodulation for Trigeminal Neuralgia. J. Korean Neurosurg. Soc. 2022, 65, 640–651. [Google Scholar] [CrossRef]
- Logghe, Y.; Smet, I.; Jerjir, A.; Verelst, P.; Devos, M.; Van Buyten, J.P. Trigeminal neuropathy: Two case reports of gasserian ganglion stimulation. Brain Behav. 2021, 11, e2379. [Google Scholar] [CrossRef]
- Taub, E.; Munz, M.; Tasker, R.R. Chronic electrical stimulation of the gasserian ganglion for the relief of pain in a series of 34 patients. J. Neurosurg. 1997, 86, 197–202. [Google Scholar] [CrossRef]
- Texakalidis, P.; Tora, M.S.; McMahon, J.T.; Greven, A.; Anthony, C.L.; Nagarajan, P.; Campbell, M.; Boulis, N.M. Percutaneous Trigeminal Stimulation for Intractable Facial Pain: A Case Series. Neurosurgery 2020, 87, 547–554. [Google Scholar] [CrossRef]
- Mehrkens, J.H.; Steude, U. Chronic electrostimulation of the trigeminal ganglion in trigeminal neuropathy: Current state and future prospects. In Operative Neuromodulation; Acta Neurochirurgica Supplements Book Series; Springer: Vienna, Austria, 2007; Volume 2, pp. 91–97. [Google Scholar] [CrossRef]
- Holsheimer, J. Electrical stimulation of the trigeminal tract in chronic, intractable facial neuralgia. Arch. Physiol. Biochem. 2001, 109, 304–308. [Google Scholar] [CrossRef] [PubMed]
- Haładaj, R.; Polguj, M.; Topol, M. Anatomical Variations of the Supraorbital and Supratrochlear Nerves: Their Intraorbital Course and Relation to the Supraorbital Margin. Med. Sci. Monit. 2019, 13, 5201–5210. [Google Scholar] [CrossRef] [PubMed]
- Zito, P.M.; Chauhan, P.R. Anatomy, Head and Neck, Supratrochlear. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557549/. (accessed on 17 November 2023).
- Dunteman, E. Peripheral nerve stimulation for unremitting ophthalmic postherpetic neuralgia. Neuromodulation 2002, 5, 32–37. [Google Scholar] [CrossRef] [PubMed]
- Hann, S.; Sharan, A. Dual occipital and supraorbital nerve stimulation for chronic migraine: A single-center experience, review of literature, and surgical considerations. Neurosurg. Focus 2013, 35, E9. [Google Scholar] [CrossRef] [PubMed]
- Johnson, M.D.; Burchiel, K.J. Peripheral stimulation for treatment of trigeminal postherpetic neuralgia and trigeminal posttraumatic neuropathic pain: A pilot study. Neurosurgery 2004, 55, 135–141; discussion 141–142. [Google Scholar] [CrossRef] [PubMed]
- Narouze, S.N.; Kapural, L. Supraorbital nerve electric stimulation for the treatment of intractable chronic cluster headache: A case report. Headache 2007, 47, 1100–1102. [Google Scholar] [CrossRef]
- Amin, S.; Buvanendran, A.; Park, K.-S.; Kroin, J.; Moric, M. Peripheral Nerve Stimulator for the Treatment of Supraorbital Neuralgia: A Retrospective Case Series. Cephalalgia 2008, 28, 355–359. [Google Scholar] [CrossRef]
- Vaisman, J.; Markley, H.; Ordia, J.; Deer, T. The treatment of medically intractable trigeminal autonomic cephalalgia with supraorbital/supratrochlear stimulation: A retrospective case series. Neuromodulation 2012, 15, 374–380. [Google Scholar] [CrossRef]
- Reed, K.L.; Black, S.B.; Banta, C.J., 2nd; Will, K.R. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: Initial experience. Cephalalgia 2010, 30, 260–271. [Google Scholar] [CrossRef]
- Schoenen, J.; Vandersmissen, B.; Jeangette, S.; Herroelen, L.; Vandenheede, M.; Gerard, P.; Magis, D. Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): A multi-centre, randomized, sham-controlled trial. J. Headache Pain 2013, 14 (Suppl. S1), P184. [Google Scholar] [CrossRef]
- Chou, D.E.; Shnayderman Yugrakh, M.; Winegarner, D.; Rowe, V.; Kuruvilla, D.; Schoenen, J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia 2019, 39, 3–14. [Google Scholar] [CrossRef] [PubMed]
- Russo, A.; Tessitore, A.; Conte, F.; Marcuccio, L.; Giordano, A.; Tedeschi, G. Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: The first Italian experience. J. Headache Pain 2015, 16, 69. [Google Scholar] [CrossRef] [PubMed]
- Jiang, L.; Yuan, D.L.; Li, M.; Liu, C.; Liu, Q.; Zhang, Y.; Tan, G. Combination of flunarizine and transcutaneous supraorbital neurostimulation improves migraine prophylaxis. Acta Neurol. Scand. 2019, 139, 276–283. [Google Scholar] [CrossRef] [PubMed]
- Reed, K.L.; Will, K.R.; Conidi, F.; Bulger, R. Concordant occipital and supraorbital neurostimulation therapy for hemiplegic migraine; initial experience; a case series. Neuromodulation 2015, 18, 297–303; discussion 304. [Google Scholar] [CrossRef] [PubMed]
- Asensio-Samper, J.M.; Villanueva, V.L.; Pérez, A.V.; López, M.D.; Monsalve, V.; Moliner, S.; De Andrés, J. Peripheral neurostimulation in supraorbital neuralgia refractory to conventional therapy. Pain Pract. 2008, 8, 120–124. [Google Scholar] [CrossRef] [PubMed]
- Kenny, B.J.; Bordoni, B. Neuroanatomy, Cranial Nerve 10 (Vagus Nerve). In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK537171/ (accessed on 7 November 2023).
- Sadler, R.M.; Purdy, R.A.; Rahey, S. Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia 2002, 22, 482–484. [Google Scholar] [CrossRef] [PubMed]
- Mauskop, A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 2005, 25, 82–86. [Google Scholar] [CrossRef]
- Trimboli, M.; Al-Kaisy, A.; Andreou, A.P.; Murphy, M.; Lambru, G. Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience. Cephalalgia 2018, 38, 1276–1285. [Google Scholar] [CrossRef]
- Nesbitt, A.D.; Marin, J.C.; Tompkins, E.; Ruttledge, M.H.; Goadsby, P.J. Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology 2015, 84, 1249–1253. [Google Scholar] [CrossRef]
- Marin, J.; Giffin, N.; Consiglio, E.; McClure, C.; Liebler, E.; Davies, B. Non-invasive vagus nerve stimulation for treatment of cluster headache: Early UK clinical experience. J. Headache Pain 2018, 19, 114. [Google Scholar] [CrossRef]
- Silberstein, S.D.; Mechtler, L.L.; Kudrow, D.B.; Calhoun, A.H.; McClure, C.; Saper, J.R.; Liebler, E.J.; Rubenstein Engel, E.; Tepper, S.J.; ACT1 Study Group. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. Headache 2016, 56, 1317–1332. [Google Scholar] [CrossRef] [PubMed]
- Goadsby, P.J.; de Coo, I.F.; Silver, N.; Tyagi, A.; Ahmed, F.; Gaul, C.; Jensen, R.H.; Diener, H.C.; Solbach, K.; Straube, A.; et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia 2018, 38, 959–969. [Google Scholar] [CrossRef] [PubMed]
- Gaul, C.; Diener, H.-C.; Silver, N.; Magis, D.; Reuter, U.; Andersson, A.; Liebler, E.J.; Straube, A. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia 2016, 36, 534–546. [Google Scholar] [CrossRef] [PubMed]
- Lenaerts, M.; Oommen, K.; Couch, J.; Skaggs, V. Can Vagus Nerve Stimulation Help Migraine? Cephalalgia 2008, 28, 392–395. [Google Scholar] [CrossRef] [PubMed]
- Hord, E.D.; Evans, M.S.; Mueed, S.; Adamolekun, B.; Naritoku, D.K. The effect of vagus nerve stimulation on migraines. J. Pain 2003, 4, 530–534. [Google Scholar] [CrossRef] [PubMed]
- Goadsby, P.J.; Grosberg, B.M.; Mauskop, A.; Cady, R.; Simmons, K.A. Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia 2014, 34, 986–993. [Google Scholar] [CrossRef] [PubMed]
- Kinfe, T.M.; Pintea, B.; Muhammad, S.; Zaremba, S.; Roeske, S.; Simon, B.J.; Vatter, H. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: A prospective observational cohort study. J. Headache Pain 2015, 16, 101. [Google Scholar] [CrossRef]
- Barbanti, P.; Grazzi, L.; Egeo, G.; Padovan, A.M.; Liebler, E.; Bussone, G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: An open-label study. J. Headache Pain 2015, 16, 61. [Google Scholar] [CrossRef]
- Tassorelli, C.; Grazzi, L.; de Tommaso, M.; Pierangeli, G.; Martelletti, P.; Rainero, I.; Dorlas, S.; Geppetti, P.; Ambrosini, A.; Sarchielli, P.; et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology 2018, 91, e364–e373. [Google Scholar] [CrossRef]
- Diener, H.C.; Goadsby, P.J.; Ashina, M.; Al-Karagholi, M.A.; Sinclair, A.; Mitsikostas, D.; Magis, D.; Pozo-Rosich, P.; Irimia Sieira, P.; Làinez, M.J.; et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019, 39, 1475–1487. [Google Scholar] [CrossRef]
- Najib, U.; Smith, T.; Hindiyeh, N.; Saper, J.; Nye, B.; Ashina, S.; McClure, C.K.; Marmura, M.J.; Chase, S.; Liebler, E.; et al. Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. Cephalalgia 2022, 42, 560–569. [Google Scholar] [CrossRef] [PubMed]
- Silberstein, S.D.; Calhoun, A.H.; Lipton, R.B.; Grosberg, B.M.; Cady, R.K.; Dorlas, S.; Simmons, K.A.; Mullin, C.; Liebler, E.J.; Goadsby, P.J.; et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology 2016, 87, 529–538. [Google Scholar] [CrossRef] [PubMed]
- Straube, A.; Ellrich, J.; Eren, O.; Blum, B.; Ruscheweyh, R. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A randomized, monocentric clinical trial. J. Headache Pain 2015, 16, 543. [Google Scholar] [CrossRef] [PubMed]
- Finnern, M.T.; D’Souza, R.S.; Jin, M.Y.; Abd-Elsayed, A.A. Cervical Spinal Cord Stimulation for the Treatment of Headache Disorders: A Systematic Review. Neuromodulation 2023, 26, 1309–1318. [Google Scholar] [CrossRef] [PubMed]
- Al-Kaisy, A.; Palmisani, S.; Carganillo, R.; Wesley, S.; Pang, D.; Rotte, A.; Santos, A.; Lambru, G. Safety and efficacy of 10 kHz spinal cord stimulation for the treatment of refractory chronic migraine: A prospective long-term open-label study. Neuromodulation 2022, 25, 103–113. [Google Scholar] [CrossRef] [PubMed]
- Wolter, T.; Kiemen, A.; Kaube, H. High cervical spinal cord stimulation for chronic cluster headache. Cephalalgia 2011, 31, 1170–1180. [Google Scholar] [CrossRef] [PubMed]
- Dario, A.; Scamoni, C.; Peron, S.; Tomei, G. A case of post-traumatic cervicogenic headache treated by cervical cord stimulation. J. Headache Pain 2005, 6, 473. [Google Scholar] [CrossRef]
- Zhao, L.; Song, T. Case Report: Short-Term Spinal Cord Stimulation and Peripheral Nerve Stimulation for the Treatment of Trigeminal Postherpetic Neuralgia in Elderly Patients. Front. Neurol. 2021, 12, 713366. [Google Scholar] [CrossRef]
- Ilhan Alp, S.; Alp, R. Supraorbital and infraorbital nerve blockade in migraine patients: Results of 6-month clinical follow-up. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 1778–1781. [Google Scholar]
- Mammis, A.; Gudesblatt, M.; Mogilner, A.Y. Peripheral neurostimulation for the treatment of refractory cluster headache, long-term follow-up: Case report. Neuromodulation 2011, 14, 432–435; discussion 435. [Google Scholar] [CrossRef]
- Elahi, F.; Reddy, C.; Bellinger, A.; Manolitsis, N. Neuromodulation of the great auricular nerve: A case report. Neuromodulation 2014, 17, 784–787. [Google Scholar] [CrossRef] [PubMed]
- Elahi, F.; Reddy, C. Neuromodulation of the great auricular nerve for persistent post-traumatic headache. Pain Physician 2014, 17, E531–E536. [Google Scholar] [CrossRef] [PubMed]
- Speciali, J.G.; Gonçalves, D.A. Auriculotemporal neuralgia. Curr. Pain Headache Rep. 2005, 9, 277–280. [Google Scholar] [CrossRef] [PubMed]
- Chim, H.; Okada, H.C.; Brown, M.S.; Alleyne, B.; Liu, M.T.; Zwiebel, S.; Guyuron, B. The auriculotemporal nerve in etiology of migraine headaches: Compression points and anatomical variations. Plast. Reconstr. Surg. 2012, 130, 336–341. [Google Scholar] [CrossRef] [PubMed]
- Simopoulos, T.; Bajwa, Z.; Lantz, G.; Lee, S.; Burstein, R. Implanted auriculotemporal nerve stimulator for the treatment of refractory chronic migraine. Headache 2010, 50, 1064–1069. [Google Scholar] [CrossRef] [PubMed]
- Zhou, L.; Ashkenazi, A.; Smith, J.W.; Jen, N.; Deer, T.R.; Zhou, C. Long-Term Clinical Outcome of Peripheral Nerve Stimulation for Chronic Headache and Complication Prevention. Anesthesiol. Pain Med. 2016, 6, e35983. [Google Scholar] [CrossRef] [PubMed]
- Ho, K.W.D.; Przkora, R.; Kumar, S. Sphenopalatine ganglion: Block, radiofrequency ablation and neurostimulation—A systematic review. J. Headache Pain 2017, 18, 118. [Google Scholar] [CrossRef]
- Tepper, S.J.; Rezai, A.; Narouze, S.; Steiner, C.; Mohajer, P.; Ansarinia, M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 2009, 49, 983–989. [Google Scholar] [CrossRef]
- Jürgens, T.P.; Barloese, M.; May, A.; Láinez, J.M.; Schoenen, J.; Gaul, C.; Goodman, A.M.; Caparso, A.; Jensen, R.H. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia 2017, 37, 423–434, Erratum in Cephalgia 2016. [Google Scholar] [CrossRef]
- Goadsby, P.J.; Sahai-Srivastava, S.; Kezirian, E.J.; Calhoun, A.H.; Matthews, D.C.; McAllister, P.J.; Costantino, P.D.; Friedman, D.I.; Zuniga, J.R.; Mechtler, L.L.; et al. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: A double-blind, randomised controlled trial. Lancet Neurol. 2019, 18, 1081–1090. [Google Scholar] [CrossRef]
- Elahi, F.; Reddy, C.G. Sphenopalatine ganglion electrical nerve stimulation implant for intractable facial pain. Pain Physician 2015, 18, E403–E409. [Google Scholar] [CrossRef] [PubMed]
- Sharan, A.; Huh, B.; Narouze, S.; Trentman, T.; Mogilner, A.; Vaisman, J.; Ordia, J.; Deer, T.; Venkatesan, L.; Slavin, K. Analysis of adverse events in the management of chronic migraine by peripheral nerve stimulation. Neuromodulation 2015, 18, 305–312; discussion 312. [Google Scholar] [CrossRef] [PubMed]
- Martelletti, P.; Jensen, R.H.; Antal, A.; Arcioni, R.; Brighina, F.; de Tommaso, M.; Franzini, A.; Fontaine, D.; Heiland, M.; Jürgens, T.P.; et al. Neuromodulation of chronic headaches: Position statement from the European Headache Federation. J. Headache Pain 2013, 14, 86. [Google Scholar] [CrossRef] [PubMed]
- Ailani, J.; Burch, R.C.; Robbins, M.S.; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021, 61, 1021–1039. [Google Scholar] [CrossRef]
- Membrilla, J.A.; Roa, J.; Díaz-de-Terán, J. Preventive treatment of refractory chronic cluster headache: Systematic review and meta-analysis. J. Neurol. 2023, 270, 689–710. [Google Scholar] [CrossRef]
- Moisset, X.; Pereira, B.; Ciampi de Andrade, D.; Fontaine, D.; Lantéri-Minet, M.; Mawet, J. Neuromodulation techniques for acute and preventive migraine treatment: A systematic review and meta-analysis of randomized controlled trials. J. Headache Pain 2020, 21, 142. [Google Scholar] [CrossRef]
Occipital Nerve | ||||||
---|---|---|---|---|---|---|
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Weiner et al. [14] | Prospective | Occipital Neuralgia | Occipital | 13 | PNS | 67% of patients with >75% pain relief; 33% of patients with >50% pain relief |
Rajat et al. [15] | Case | Occipital Neuralgia | Occipital | 1 | PNS | 0/10 pain scale at five- and twelve-month follow-ups |
Salmasi et al. [16] | Case | Occipital Neuralgia | Occipital | 3 | PNS | 55% (range 25–90%) pain relief at nine (range 6–16 months) months |
Oh et al. [17] | Technical Report | Occipital Neuralgia | Occipital | 10 | PNS (C1-3 paddle-style electrode) | At one month, 80% patients with >90% pain reduction; 20% patients with 75–90% pain reduction; at six months, 78% patients with >90% pain reduction, 11% patients with 50–75% pain reduction |
Kapural et al. [18] | Case-series | Occipital Neuralgia | Occipital | 6 | PNS | 71% decrease in VAS and 72% decrease in pain disability index scores |
Slavin et al. [19] | Retrospective | Occipital Neuralgia | Occipital | 14 | PNS | At mean follow-up of 22 months (range five-32 months), 50% patients pain-free, 30% with significant pain relief |
Raoul et al. [20] | Retrospective | Occipital Neuralgia | Occipital | 60 | PNS | 72.2% decrease in VAS and 72.7% decrease in number of headache days per month after one year |
Miller et al. [21] | Prospective | Short-lasting Unilateral Neuralgiform Headache (SUNCT syndrome) | Occipital (bilateral) | 31 | PNS | At mean follow-up of 44.9 months (range 13–89 monts), 69% decrease in mean daily attack frequency; 38.7% of patient pain-free at the final follow-up |
Pascual et al. [22] | Crossover | Hemicrania Continua | Suboccipital | 6 | PNS | At median follow-up of 13.5 months (range 6–21 months), 67% patients with 80–95% improvement, 17% patients with 30% improvement, and 17% patients with worsening pain by 20% |
Balossier et al. [23] | Retrospective | Trigeminal Neuralgia | Occipital | 7 | PNS | Mean follow-up of 59 months (range 2–106 months); mean pain relief of 86.7% (range 70–100%); at last follow-up, mean pain relief of 58% (range 0–100%) |
Mueller et al. [24] | Prospective | Cluster Headache | Occipital | 10 | PNS | 90% patients with improvement; mean overall improvement of 44% (range 20–90%) of attacks; 30% patients with up to 19 days of pain-free period |
Magis et al. [25] | Prospective | Cluster Headache | Suboccipital | 8 | PNS | Mean follow-up of 15.1 (range 3-22 months) months; 25% patients pain-free at 16 and 22 months, 38% patients with 90% attack frequency reduction, 25% patients with 40% improvement |
Magis et al. [26] | Prospective | Cluster Headache | Suboccipital | 15 | PNS | Mean follow-up of 36.82 months; 80% patients with 90% improvement in pain, 60% patients pain-free, 13% patients with no or mild improvement |
Leone et al. [27] | Monocentric, Open-Label | Cluster Headache | Occipital | 35 | PNS | Median follow-up of 6.1 (range 1.6–10.7 years) years; decrease in mean number of daily attacks from 5.7 to 2.4; 66.7% patients with >50% reduction in number of headache per day |
Burns et al. [28] | Prospective | Cluster Headache | Occipital (bilateral) | 14 | PNS | Median follow-up of 17.5 (range four-35 months) months; 71% patients with improvement in frequency, severity, or duration; 30% patients with 90% improvement, 30% patients with >40% improvement, 40% patients with 20–30% improvement |
Burns et al. [29] | Prospective | Cluster Headache | Occipital (bilateral) | 8 | PNS | Median follow-up of 20 (range eight-27 months) months; 75% patients with improvements; 25% patients with >90% improvement in attacks, 38% patients with >40% improvement, 13% patients with >25% improvement |
Fontaine et al. [30] | Cohort | Cluster Headache | Occipital (bilateral) | 13 | PNS | Mean follow-up of 14.6 (range three-34 months) months; 77% patients with improvements within a few days of implantation; eight patients with 68% decrease in mean attack frequency and 49% decrease in mean attack intensity on NRS at one-year follow-up |
Garcia-Ortega et al. [31] | Retrospective | Cluster Headache | Occipital | 17 | PNS | 60% patients with complete remission, 100% patients with >80% decrease in attack frequency with a mean reduction of 42% in residual headache intensity |
Miller et al. [32] | Prospective | Cluster Headache | Occipital (bilateral) | 51 | PNS | Mean follow-up of 39.17 months; 52.9% patients with >50% decrease in daily attack frequency, 47.1% patients with six months of continuous pain relief; of 27 patients using preventive medications at baseline, four ceased all preventive medication use and 17 reduced use |
Tepper et al. [33] | Prospective | Cluster Headache | Occipital (bilateral) | 67 | PNS | At three-month follow-up, 75% patients with >30% reduction in attack frequency; at 12 months follow-up, 64% patients with >30% reduction in attack frequency and 59% patients with >50% reduction |
Wilbrink et al. [34] | Randomized Controlled Trial (multicenter, double-blind, phase 3) | Cluster Headache | Occipital | 131 | PNS | Ten-day run = in phase, 24-week treatment period; Decrease in median weekly mean attack frequency (MAF) from 7.38 to 5.21 after ONS onset; between weeks 21–24 and 45–48, about 50% of patients with >50% pain relief |
Popeney et al. [35] | Case Series | Migraine | Occipital | 25 | PNS | Mean follow-up of 18.3 (range nine-36 months) months; Mean headache frequency reduction from 75.6 days to 37.5 days; mean severity on a NRS scale of 0–10 decreased from 9.32 to 5.72 |
Oh et al. [17] | Prospective | Migraine | Occipital | 10 | PNS (C1-3 paddle electrode) | At one-month follow-up, 90% patients with >90% pain reduction, 10% patients with 75–90% reduction in pain; at six-month follow-up, 78% patients with >90% pain reduction, 22% patients with 75–90% pain reduction |
Rodrigo et al. [36] | Prospective | Migraine | Occipital | 41 | PNS | Mean follow-up of 9.4 years; VAS decrease by 4.9, the number of migraine days per month reduction by 59.2%; 13.9% patients with permanent implantation pain-free at last visits |
Ashkan et al. [37] | Prospective | Migraine | Occipital | 112 | PNS | At three-month follow-up, mean reported pain relief of 25.1% and 21.7% patients with >50% pain relief; at nine- and 12-month follow-ups, reported pain relief of 30.8%, and 28.5% patients with >50% relief |
Schwedt et al. [38] | Retrospective | Migraine | Occipital (eight bilateral; seven unilateral) | 15 | PNS | Mean follow-up of 17.8 (range 6–36 months) months; severity reduction from 6.75 to 4.5 on a 0–10 scale; MIDAS from 170 to 116; HIT-6 from 73 to 61; BDI-II from 19 to 11.5 |
Matharu et al. [39] | Case Series | Migraine | Suboccipital (bilateral) | 8 | PNS | Mean follow-up of 1.5 years (range seven months to three years); 50% patients pain-free with only rare breakthrough headaches; 25% with very good responses with suppression of headaches |
Serra et al. [40] | Prospective, randomized cross-over | Migraine | Occipital | 34 | PNS | Trial period of 15–30 days; Average follow-up of 45 days (range 12 to 122 days); 9% patients with >50% reduction in the number of attacks, 22% patients with >50% reduction in the severity of attacks, 66% patients with >50% reduction in both number and severity |
Silberstein et al. [41] | Randomized Controlled Trial (double-blind) | Migraine | Occipital | 268 | PNS | 157 subjects with permanent implantation; 59.5% patients > 30% reduction in headache days and/or pain intensity, 47.8% patients > 50% in headache days |
Saper et al. [42] | Randomized Controlled Trial | Migraine | Occipital | 75 | PNS | At three months follow-up, 39% of adjustable stimulation (AS) group, 6% of preset stimulation (PS) group, and 0% of medical management (MM) group with reduction of >50% in number of headache days per month |
Slotty et al. [43] | Randomized Controlled Trial | Migraine | Occipital (bilateral) | 8 | PNS | No significant differences in improvement of VAS between “effective”, “subthreshold”, and “no” stimulation from the prior ONS |
Mekhail et al. [44] | Randomized Controlled Trial | Migraine | Occipital | 20 | PNS | Randomized to either active or no stimulation for 12 weeks, followed by 40 weeks of active simulation; after twelve week randomization period, 60% active group with >30% reduction in VAS, 20% control group with >30% reduction in VAS; at the end of 52 weeks/open phase, 60% patients with >30% reduction in VAS, 25% patients with >50% reduction in VAS |
Liu et al. [45] | Randomized Controlled Trial | Migraine | Occipital | 110 | PNS | Randomized into transcutaneous ONS (2 Hz, 100 Hz, 2/100 Hz, sham) and treatment with topiramate; only the 100 Hz tONS and topiramate groups with significant differences in reduction of headache days compared to sham |
Deshpande et al. [46] | Case | Complicated Migraine, Occipital Neuralgia, combined (phophobia, temporary bilateral vision loss, slurred speech, ptosis, hemiplegia) | Occipital, bilateral subcutaneous temporal region | 1 | PNS | At 24-month follow-up, 50% reduction in the onset of headache and resolution of neurologic deficits |
Trentman et al. [47] | Prospective | Primary Headache, combined | Occipital | 9 | PNS | 62.5% patients with excellent, 25% with fair, and 12.5% with poor responses; mean decrease of 28.5 in headache days, average decrease in headache severity score of 0.88 |
Slavin et al. [48] | Prospective | Craniofacial Pain | Infraorbital | 30 | PNS | 22/30 patients with 50% reduction in pain intensity, of whom three had infraorbital, four had supraorbital, 13 had occipital, and one had a combination of infraorbital and occipital, and one had a combination of supraorbital and occipital stimulations; mean follow-up of 35 months (range 1–77 months); 73% of 22 patients with implantation with >50% improvement in pain intensity and 13.5% with <50% improvement. |
Trigeminal Ganglion | ||||||
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Logghe et al. [50] | Case | Trigeminal Neuropathy | Trigeminal Ganglion | 2 | PNS | Total resolution of symptoms within weeks to months after implantation in both patients |
Taub et al. [51] | Prospective | Trigeminal Neuropathy | Trigeminal Ganglion | 34 | PNS | Of the group with permanent implantation, 53% patients with >50% pain relief |
Texakalidis et al. [52] | Retrospective Case Series | Trigeminal Neuropathy | Trigeminal Ganglion | 59 | PNS | 70% patients with positive results with a trial of trigeminal stimulation; history of oral surgery, facial trauma predictive of failure |
Kustermans et al. [6] | Retrospective | Trigeminal Neuropathy | Trigeminal Ganglion | 22 | PNS | At the initial follow-up, 88% patients with >50% reduction of pain; at six-month follow-up, 93.8% patients with some level of pain relief; at 24 months, 46.7% patients with some level of pain relief |
Mehrkens et al. [53] | Prospective | Trigeminal Neuropathy | Trigeminal Ganglion | 321 | PNS | At a long-term follow-up (range five to 25 years), 52% patients with >50% pain reduction, 82% patients with good or excellent analgesia |
Holsheimer et al. [54] | Prospective | Trigeminal Neuralgia | Trigeminal Ganglion | 267 | PNS | 48% patients with >50% long-term pain relief; patients with postherpetic neuralgia with low success rate of 10% |
Supraorbital/Supratrochlear Nerve | ||||||
Author [Citation] | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Dunteman et al. [57] | Case | Postherpetic Neuralgia | Supraorbital | 2 | PNS | Significant reduction in VAS score and discontinuation of opioid medication |
Hann et al. [58] | Prospective | Postherpetic Neuralgia | Supraorbital, Occipital, combined | 14 | PNS | Follow-up ranging from three to 60 months; 71% patients > 50% reduction in pain severity with mean VAS score reduction of 3.92 |
Johnson et al. [59] | Prospective | Postherpetic Neuralgia | Supraorbital, Infraorbital | 10 | PNS | At the mean follow-up of 26.6 months post-transplantation, 70% patients with >50% reduction in pain and decreased medication use |
Narouze et al. [60] | Case | Cluster | Supraorbital | 1 | PNS | Successful relief and resolution of symptoms after implantation |
Amin et al. [61] | Retrospective | Cluster | Supraorbital | 16 | PNS | Ten patients with permanent implantation; significant reduction in headache scores after five to seven days of stimulation, persisting up to thirty weeks; significant decrease in morphine equivalent required |
Vaisman et al. [62] | Prospective | Cluster | Supraorbital | 5 | PNS | VAS scores decreased from 8.9 to 1.6; reported improvement in frequency and intensity of attacks |
Reed et al. [63] | Prospective | Cluster | Supraorbital, Occipital, combined | 7 | PNS | Mean follow-up of 25.2 months; all patients with improvements in functional status, VAS, and frequency of headaches |
Schoenen et al. [64] | Randomized Controlled Trial (multicenter) | Cluster | Supraorbital | 67 | PNS | Significant decrease in mean number of migraine days, difference in 50% responder rate, monthly migraine attacks, monthly headache days, monthly acute anti-migraine drug intake |
Chou et al. [65] | Randomized Controlled Trial (multicenter, double-blind) | Migraine | Supraorbital, Supratrochler, combined | 106 | PNS | At one, two, and 24 h, mean change in pain score significantly reduced in the verum group compared to the sham; 29% of verum group pain-free, while 6% of sham group pain-free |
Russo et al. [66] | Prospective | Migraine | Supraorbital | 24 | PNS | 81% patients with >50% reduction in migraine attacks, 75% patients with >50% reduction in migraine days per month |
Jiang et al. [67] | Randomized Controlled Trial | Migraine | Supraorbital | 154 | PNS | At three-month follow-up, more pronounced reduction in days of migraine per month in the combination group of flunarizine with neurostimulation; 50% responder rate of 78.43% in combination group, 46.15% in flunarizine monotherapy, and 39.22% in supraorbital stimulation monotherapy |
Reed et al. [68] | Prospective | Hemiplegic Migraine | Supraorbital, Occipital, combined | 4 | PNS | Follow-up period running 6 to 92 months post-transplantation; mean headache frequency by 92% from 30 to 2.4 headache days per month; VAS reduction by 44% from 9.5 to 5.3; frequency of hemiplegic episode reduction by 96% from 7.5 to 0.25 |
Asensio-Samper et al. [69] | Case | Supraorbital Neuralgia, Traumatic | Supraorbital | 1 | PNS | 14-day trial resulting in improvement of VAS score; permanent implantation to discontinue medications |
Vagus Nerve | ||||||
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Sadler et al. [71] | Case | Non-Specific/ Combination Primary Headache; history of epilepsy | Vagus | 1 | PNS | Reduction in migraine attack frequency from three in one month to three in 13 months |
Mauskop et al. [72] | Case | Migraine (4), Cluster (6) Headaches | Vagus | 6 | PNS | 33% patients with “excellent” response, 33% with “good” response to vagus nerve stimulation |
Trimboli et al. [73] | Prospective | Short-Lasting Neuralgiform Headache Attacks with Autonomic Symptoms (SUNA) | Vagus | 2 | PNS | At three-month follow-up, the patients with SUNA reported noticeable improvement |
Trimboli et al. [73] | Prospective | Hemicrania Continua | Vagus | 4 | PNS | At three-month follow-up, 50% of the patients with HC reported meaningful improvement; one patient with 72.7% decrease in headache exacerbations at three months |
Trimboli et al. [73] | Prospective | Cluster Headache | Vagus | 12 | PNS | At three-month follow-up, 8% of patients with >30% reduction in weekly CH frequency and reduction in oxygen use per week, 17% patients with slight improvement in weekly frequency, 25% patients with no changes to headache, and 50% with worsening of CH frequency |
Nesbitt et al. [74] | Cohort, Open-Label | Cluster Headache | Vagus | 19 | PNS | Mean improvement in condition from baseline by 50%; a near 50% reduction in attack frequency in patients using nVNS preventively |
Marin et al. [75] | Retrospective | Cluster Headache | Vagus | 30 | PNS | 53% patients used as preventive therapy, 3% patients used exclusively for acute, and 43% patients for both; mean follow-up of 7.6 (range 0.0 to 27.5 months) months; 10% patients free of attack |
Silberstein et al. [76] | Randomized Controlled Trial (double-blind) | Cluster Headache | Vagus | 150 | PNS | No significant differences in response rate, sustained treatment response rate, the percentage of patients who were responders, and of those who were pain relief for at least 50% of treated attacks |
Goadsby et al. [77] | Randomized Controlled Trial (double-blind) | Cluster Headache | Vagus | 102 | PNS | Randomized to a sham or active nVNS group for two weeks, then an open-label period for two weeks; significantly higher proportion of treated attacks that achieved pain-free status in nVNS than that of sham in the episodic CH group |
Gaul et al. [78] | Randomized Controlled Trial (open-label) | Cluster Headache | Vagus | 97 | PNS | At four-week follow-up, statistically significant reduction in the number of attacks per week in nVNS group compared to the control (−5.9 vs. −2.1); during the randomized phase, 57% decrease in the frequency of abortive medication use in the treatment group |
Trimboli et al. [73] | Prospective | Migraine | Vagus | 23 | PNS | 8.7% patients with >30% reduction of headache days, 17.4% with <30% reduction, 30.4% patients with worsening number of headache days, and 43.5% patients with no change |
Lenaerts et al. [79] | Retrospective | Migraine | Vagus | 34 | PNS | Mean follow-up of 17 (range 4–36 months) months; 80% patients with >50% reduction in monthly frequency, in the first three month of placement |
Hord et al. [80] | Retrospective | Migraine | Vagus | 62 | PNS | 25% patients with complete pain relief, 25% patients with mild pain relief, and 50% patients with a lot of pain relief; 100% patients with a dcrease in migraine frequency |
Goadsby et al. [81] | Open-Label, Single-Arm, Multiple Attack, Pilot | Migraine | Vagus | 30 | PNS | For the first attack, after two hours of treatment, 21% patients with baseline moderate or severe headache reported pain-free and 47% patients reported partial pain relief |
Kinfe et al. [82] | Prospective, Observational Cohort | Migraine | Vagus | 20 | PNS | Median pain VAS reduction from 8 (range 7.5 to 8) to 4 (range 3.5 to 5); mean number of headache days per month decreased by 39.5% in tota; migraine attacks per month decreased by 38.4%l |
Barbanti et al. [83] | Open-Label, Single-Arm, Multicenter | Migraine | Vagus | 50 | PNS | 56.3% patients with >50% pain reduction at one hour, 62.9% of whom reported pain-free; 64.6% patients with >50% pain reduction at two hours, 61.3% of whom reported being pain-free |
Tassorelli et al. [84] | Randomized Controlled Trial | Migraine | Vagus | 248 | PNS | At 120 min, statistically significant difference in pain-free responder rate in nVNS compared to sham; nVNS superior to sham in abortion of the first treated attack at 30 and 60 min, but not at 120 min |
Diener et al. [85] | Randomized Controlled Trial (prospective, multicenter, double-blind, parallel-group) | Migraine | Vagus | 477 | PNS | No statistically significant difference in the number of migraine days per month, percentage of patients with at least 50% reduction in number of migraine days, mean reductions in the number of headache days, nor reductions in the number of acute medication days |
Najib et al. [86] | Randomized Controlled Trial | Migraine | Vagus | 336 | PNS | After 12-week of double-blind period, nVNS group with statistically significant difference in the proportion of >50% reduction in the number of migraine days |
Silberstein [87] | Prospective, Multicenter, Double-Blind, Sham-Controlled, Pilot | Migraine | Vagus | 73 | PNS | No statistically significant difference in the number of headache days during the randomized phase; statistically significant decrease in mean headache days after eight months in the nVNS group during the open-label phase |
[88] | Randomized Controlled Trial (Monocentric, Prospective, Double-Blind) | Migraine | Vagus | 46 | PNS | 36.4% reduction in headache days in the 1 Hz group and 17.4% reduction in the 25 Hz group; 29.4% in the 1 Hz and 13.6% in the 25 Hz group reported >50% improvement in headache days |
Cervical Spinal Cord | ||||||
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Al-Kaisy et al. [90] | Prospective, Long-Term, Single-Center, Open-Label | Migraine | Cervical Spinal Cord | 20 | SCS (10 kHz) | At 52-week follow-up, 60% patients with >30% reduction in mean monthly migraine days (MMD) and 50% patients with >50% reduction in mean MMD |
Wolter et al. [91] | Prospective | Cluster Headache | Cervical Spinal Cord | 7 | SCS (high cervical epidural electrodes) | Mean follow-up of 23 (range three to 78 months) months; decrease in attacks per day from 5.0 (range 1.7–10.0 attacks/day) to 1.4 (range 0–3.5 attacks/day); reduction in mean VAS from 7.4 to 4.5 |
Dario et al. [92] | Case | Post-Traumatic Headache | Cervical Spinal Cord | 1 | SCS (cephalad end of C3–C4) | 80% improvement of neck pain and resolution of supraorbital pain |
Zhao et al. [93] | Case | Postherpetic Neuralgia | Cervical Spinal Cord | 1 | SCS (C1–C2; 40 Hz) | Reduction in NRS score from 7–9 to 1–2 post-implantation |
Infraorbital Nerve | ||||||
Author [Citation] | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Mammis et al. [95] | Case | Cluster Headache | Infraorbital | 1 | PNS | At 36-month follow-up, reduction in frequency of headache from three-to-four episodes per day to three-to-four episodes per month |
Great Auricular Nerve | ||||||
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Elahi et al. [96] | Case | Migraine | Great Auricular | 1 | PNS | At six-month follow-up, significant alleviation of pain |
Elahi et al. [97] | Case | Post- Traumatic Headache | Great Auricular | 1 | PNS (C2-C3 branches) | At six-month follow-up, >90% reduction in headache frequency |
Auriculotemporal Nerve | ||||||
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Simopoulos et al. [100] | Case | Migraine | Auriculotemporal (bilateral) | 1 | PNS | At 16-month follow-up, MIDAS decreased from grade IV (severe disability) to grade II (mild disability), and average pain intensity from 8–9 to 5 on a 0–10 scale |
Zhou et al. [101] | Prospective | Chronic Headache | Auriculotemporal | 20 | PNS | At three-month follow-up, reduction in mean total pain index (TPI) from 516 to 74.8 post-implantation |
Sphenopalatine Ganglion | ||||||
Author | Study Type | Condition | Targeted Nerve(s) | Number of Participants | Type of Intervention | Outcome |
Tepper et al. [103] | Prospective | Migraine | Sphenopalatine Ganglion | 11 | PNS | Two patients with a complete resolution of migraine headaches within three minutes of stimulation, three patients with reduction in pain, and five patients with no response, and one not stimulated |
Jürgens et al. [104] | Open-Label Prospective | Cluster Headache | Sphenopalatine Ganglion | 33 | PNS | 45% patients with >50% attacks, >50% reduction in attack frequency |
Goadsby et al. [105] | Double-Blind, Randomized Controlled Trial | Cluster Headache | Sphenopalatine Ganglion | 93 | PNS | 62.46% of SPG stimulation group with pain relief, while 38.87% of control group with pain relief |
Elahi et al. [106] | Case | Facial Pain | Sphenopalatine Ganglion (pteyrgopalatine fossa) | 1 | PNS | Complete discontinuation of opioid-based medication |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pak, R.J.; Ku, J.B.; Abd-Elsayed, A. Neuromodulation for Craniofacial Pain and Headaches. Biomedicines 2023, 11, 3328. https://doi.org/10.3390/biomedicines11123328
Pak RJ, Ku JB, Abd-Elsayed A. Neuromodulation for Craniofacial Pain and Headaches. Biomedicines. 2023; 11(12):3328. https://doi.org/10.3390/biomedicines11123328
Chicago/Turabian StylePak, Ray J., Jun B. Ku, and Alaa Abd-Elsayed. 2023. "Neuromodulation for Craniofacial Pain and Headaches" Biomedicines 11, no. 12: 3328. https://doi.org/10.3390/biomedicines11123328